Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

• 主要な著者: Yu-Ching Weng (著者), Chien-Shan Chiu (著者), Tseng-Hsi Lin (著者), Jui-Lung Shen (著者), Chii-Shuenn Yang (著者), Joe-Bin Chen (著者)
• フォーマット: 図書
• 出版事項: Wolters Kluwer Medknow Publications, 2016-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40-60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic...